Non-Segmental Vitiligo study: ACT-777991
Official title A Study to Learn How Safe ACT-777991 is and How Well it Works in Adults With Non-segmental Vitiligo
ClinicalTrials.gov ID: NCT07667569
What this study is testing
What is ACT-777991?
ACT-777991 is an investigational medicine, taken by mouth once daily, being studied as a potential treatment for non-segmental vitiligo.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this clinical trial is to learn how well ACT-777991 works, how safe it is and how well it is tolerated by adults with non-segmental vitiligo.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 24 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- F-VASI score ≥ 0.3 based on BICR at Screening.
- T-VASI score ≥ 5 based on investigator assessment at Screening and Randomization.
- Total body surface area (BSA) involvement, including the face, ≤ 50% based on investigator assessment at Screening and Randomization.
- Participants must agree not to use therapeutic agents and procedures to treat vitiligo from Screening until Participant Last Visit.
You likely can't join if
- Clinical diagnosis of other forms of vitiligo (e.g., segmental) or other hypo- or depigmentation disorders (e.g., piebaldism, leukoderma...
- Any autoimmune disease, except adequately treated thyroid disease.
- History of systemic immunotherapy treatment, including JAK inhibitors, for any inflammatory disease in the 12 months prior to Randomization.
- History of topical JAK inhibitors for any inflammatory disease in the 6 weeks prior to Screening.
- Use of laser or light-based treatment (phototherapy), including tanning beds, in the 8 weeks prior to Screening.
- eGFR \< 90 mL/min/1.73 m\^2, defined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation, at Screening.
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 24 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.